Covered recipient · General Payments record
KARL K FUKUNAGA
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
General Payments · PY2018–2024
$4,010.91
- Reported across 207 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $696.61 | 31 |
| Education | $20.00 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $266.73 | 11 |
| PFIZER INC. | $202.64 | 10 |
| Gilead Sciences, Inc. | $75.97 | 3 |
| Ardelyx, Inc. | $59.35 | 2 |
| Ipsen Biopharmaceuticals, Inc | $41.18 | 2 |
| Merck Sharp & Dohme Corporation | $18.10 | 1 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.09 | 1 |
| Phathom Pharmaceuticals, Inc. | $18.02 | 1 |
| AIMMUNE THERAPEUTICS, INC. | $16.53 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (32)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $11.00 | 01/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103759596 | CMS |
| ABBVIE INC. | $27.42 | 01/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103759598 | CMS |
| ABBVIE INC. | $5.38 | 01/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103759600 | CMS |
| ABBVIE INC. | $12.37 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103759602 | CMS |
| ABBVIE INC. | $28.83 | 02/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103759604 | CMS |
| ABBVIE INC. | $9.32 | 04/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103759606 | CMS |
| ABBVIE INC. | $15.89 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103759608 | CMS |
| ABBVIE INC. | $104.17 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103759610 | CMS |
| ABBVIE INC. | $22.82 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103759612 | CMS |
| ABBVIE INC. | $18.47 | 11/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103759614 | CMS |
| ABBVIE INC. | $11.06 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103759616 | CMS |
| AIMMUNE THERAPEUTICS, INC. | $16.53 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146975012 | CMS |
| Ardelyx, Inc. | $31.29 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146681055 | CMS |
| Ardelyx, Inc. | $28.06 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146681057 | CMS |
| Gilead Sciences, Inc. | $23.61 | 09/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133790791 | CMS |
| Gilead Sciences, Inc. | $30.58 | 09/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133790793 | CMS |
| Gilead Sciences, Inc. | $21.78 | 12/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133790795 | CMS |
| Ipsen Biopharmaceuticals, Inc | $21.18 | 05/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1091980221 | CMS |
| Ipsen Biopharmaceuticals, Inc | $20.00 | 06/17/2024 | Education | Undisputed | 01/23/2026 | 1091980223 | CMS |
| Merck Sharp & Dohme LLC | $18.10 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141569526 | CMS |
| PFIZER INC. | $17.96 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131104125 | CMS |
| PFIZER INC. | $21.74 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131181389 | CMS |
| PFIZER INC. | $20.89 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131518180 | CMS |
| PFIZER INC. | $15.67 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131685270 | CMS |
| PFIZER INC. | $20.84 | 06/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131684587 | CMS |
| PFIZER INC. | $12.74 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132056486 | CMS |
| PFIZER INC. | $20.22 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131989895 | CMS |
| PFIZER INC. | $22.32 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132071829 | CMS |
| PFIZER INC. | $27.35 | 11/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132118926 | CMS |
| PFIZER INC. | $22.91 | 12/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131089552 | CMS |
| Phathom Pharmaceuticals, Inc. | $18.02 | 04/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151063233 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.09 | 12/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153590702 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.